The Purity Headline Is Not the Whole Story: Contaminant Screening Before a Reproducibility Review

ByNelson Adusei

Why a purity figure cannot carry a reproducibility review on its own

Reproducibility reviews rarely fail on the headline number. They fail on the details behind it: which batch was used, which sample was tested, what else was in the vial, and whether the documentation still matches the material in hand. A certificate that reports a purity percentage, however impressive, answers only one of several questions a reviewer will ask. Purity, identity and contamination are three separate analytical questions, and a materials manager who treats them as interchangeable is storing up trouble for the review stage.

High-performance liquid chromatography (HPLC) purity is, by design, a relative measurement. It describes the proportion of the integrated signal attributable to the main peak, gives no direct reading of inorganic contaminants, and offers no direct evidence that the peak is the compound the label claims. A vial can clear a purity threshold while carrying a heavy-metal burden or an endotoxin load that was never screened — or, more commonly, while nobody in the chain can produce the document that would rule those out. That distinction matters most when an assay is repeated, because the contaminant profile, not the purity decimal, is what tends to vary between lots.

Research Sciences describes its testing framework as covering purity, identity, heavy metals and endotoxin evaluation of submitted samples, with heavy-metal and endotoxin screening alongside CoA documentation presented as a later expansion of that framework. It also publishes a homepage purity claim and a figure of over 99.1% for UK research materials. These are the shop’s published figures, not independently audited statistics, and they should be reconfirmed against the live site and, more importantly, against the batch-specific CoA that actually accompanies the vial. A category-level claim is a marketing statement; a batch CoA is a document you can cite.

What to request when you ask for the tests

The practical move is to stop asking suppliers whether a product is “tested” and start asking which tests were run, on which sample, and against which batch. Those three questions expose the gap between a purity headline and a contaminant profile faster than any other.

Ask for the batch CoA, not the category page

Research Sciences states that every compound includes a CoA for purity and identity, and its homepage lists “CoAs Janoshik Analytical Reports”. Where such a report is referenced, ask to see the CoA that accompanies the specific batch in question rather than a representative example. Read it critically: confirm the sample identity, the methods named, the reported values and the report reference, then check that the reference matches the vial you are holding.

Understand what an ITR does and does not prove

The shop’s FAQs note that restocked products may carry the same Internal Test Reference (ITR) as earlier stock, and that an ITR links to associated sample testing reports. It does not confirm that separate deliveries derive from the same production lot, nor that each delivery has been independently tested. That is a meaningful limitation for anyone comparing a current vial with one used in an earlier study. If your review spans two orders of the same catalogue item, the ITR alone will not reconcile them; you need the individual documentation path for each delivery.

Identify the vial precisely

Vial labels combine a SKU code and an expiry date — for example, BPC10-03/27 — and link to the corresponding CoA. Quote that reference whenever you contact the shop about documentation; it is the shortest route to the right report. Note too that vial cap colours and other packaging may vary, and that cap colour is not an indicator of identity, analytical quality or manufacturing origin. Neither is the appearance of the lyophilised cake.

Ask about excipients and screening together

The FAQs disclose that all peptides contain trace amounts of mannitol, an excipient used to support lyophilisation and storage. It is worth recording in your methods, because excipient content is one more variable between formats. Alongside it, ask specifically whether heavy-metal and endotoxin screening was performed on the batch, and read the reported result rather than a summary sentence. A laboratory assembling a panel for a review can Buy peptides from the current catalogue and then open the individual product page for its CoA before committing the material to a study design.

Documenting the batch trail from receipt to assay

Once the tests have been requested and received, the review depends on the trail you build around them. A CoA is only half the record; the other half describes what happened to the material after it arrived. Record the catalogue item, the vial reference, the ITR where present, the CoA reference and the storage history for every vial entering a study. Two vials with identical labels can have entirely different handling histories, and the reviewer’s question is usually about the history, not the label.

A worked scenario

Consider a laboratory that runs an in-vitro assay in one quarter and repeats it six months later. The second delivery carries the same ITR but a different cap colour, and the analyst assumes equivalence. When the results diverge, the review cannot tell whether the difference comes from the biological system, the assay reagents, or a genuine difference in the material. Had the analyst recorded the two delivery dates, the separate CoA paths and the storage conditions, the question would have been answerable. Instead, the ITR has created a false sense of continuity. Treat same-ITR deliveries as separate until the documentation says otherwise, and describe them that way in the report.

Handling variables worth logging

Handling language belongs firmly inside the in-vitro workflow. Allow vials to reach room temperature before opening, work in a clean environment, and remove only the quantity required for the experiment. Store lyophilised material at −20 °C or below, sealed with desiccant and protected from moisture, heat and light, and avoid repeated freeze–thaw cycles. Reconstituted material is less stable and should be held at 2–8 °C for short-term laboratory use. Where an assay requires reconstitution, record the diluent volume and the resulting concentration for the in-vitro system; the shop’s reconstitution calculator is a laboratory aid for that arithmetic, not for any other purpose.

Formulation choices that simplify review

The shop does not supply blended peptides and recommends purchasing compounds individually, combining them only within a controlled experimental design. That advice is worth taking seriously at the review stage: a single-component vial allows a contaminant finding, if one arises, to be attributed to one material rather than to an unknown mixture.

Compliance details that belong in the record

Every entry in the chain should carry the compliance framing. Materials are supplied strictly for controlled laboratory and analytical research and are not for human or veterinary use; they are not medicines, medical devices, injectables, treatments or food supplements. The purchaser is responsible for lawful use, safe handling, storage and disposal, and for compliance with UK requirements including COSHH and laboratory safety standards. Suppliers and purchasers alike should keep that status visible in study notes, because it shapes what the material can legitimately be used to demonstrate. Published claims such as “≥99% Verified Purity” and “24hr UK Delivery” should be reconfirmed on the live site, and the batch CoA treated as the operative document wherever a figure matters to the study. Materials remain not for human or veterinary use at every stage of the workflow.

Related Posts:

Similar Posts